INTRODUCTION
============

Vaccinia-related kinase 1 (VRK1), a novel family of mammalian serine/threonine protein kinases, was initially identified by its homo­logy to the catalytic domain of the vaccinia virus B1R kinase, which is essential for viral DNA replication (Rempel *et al.*, [@B38]; Nezu *et al.*, [@B34]; Nichols and Traktman, [@B35]; Klerkx *et al.*, [@B22]). VRK1 shows ubiquitous expression in embryonic and adult tissues. This gene is especially highly expressed in proliferating tissues, such as fetal liver, testis, and thymus and in several cancer cell lines (Nezu *et al.*, [@B34]; Santos *et al.*, [@B40]). A previous study demonstrated that VRK1 is a nuclear kinase that stabilizes the intracellular protein levels of p53 by a posttranscriptional modification and thus affects p53-dependent transcription (Vega *et al.*, [@B44]). Moreover, VRK1 phosphorylates and associates with other transcription factors, such as ATF2 or c-Jun, resulting in an incremental increase in transcriptional activity (Sevilla *et al.*, [@B41], [@B41]). In addition, it has been shown that VRK1 may modulate the association of Barrier to Autointegration Factor (BAF) with nuclear components and thus play a role in maintaining appropriate nuclear architecture (Nichols *et al.*, [@B36]; Gorjánácz *et al.*, [@B13]). According to recent reports, VRK1 phosphorylates histone H3 on Thr-3 and Ser-10 required for mitotic chromatin condensation (Kang *et al.*, [@B21]). Additionally, VRK1 mediates cyclin D1 expression through the phosphorylation of cAMP response element-binding protein (CREB) (Kang *et al.*, [@B20]). Mouse VRK1 is composed of three differentially spliced isoforms: full-length, lacking exon 12 (mVRK1Δ), or lacking exons 12 and 13 (mVRK1ΔΔ) (Nichols and Traktman, [@B35]). The mVRK1ΔΔ isoform is identical to human VRK1 in length and alignment of carboxy termini of the sequences (Nichols and Traktman, [@B35]). However, little is known about the cellular functions and the upstream regulatory elements of these murine kinases.

Protein kinase C (PKC), a family of serine/threonine protein kinases, is activated by diverse stimuli and participates in cellular processes such as growth, differentiation, and apoptosis (Hug and Sarre, [@B16]; Griner and Kazanietz, [@B14]). PKC is composed of three subclasses consisting of the classical (α, βI, βII, and γ), novel (δ, ε, η, and θ), and atypical (ζ and ι/λ) PKC isoforms. In addition, two other members, PKCμ and PKCν, exhibit unique characteristics (Johannes *et al.*, [@B19]). Activation of PKC is usually associated with membrane translocation, and prolonged cellular exposure to PKC activators can cause its degradation or down-regulation (Lu *et al.*, [@B31]). PKC can also be activated by cleavage to generate an active catalytic fragment freed from inhibition by the regulatory domain (Emoto *et al.*, [@B11]; Smith *et al.*, [@B43]; Basu *et al.*, [@B1]).

PKCδ has been shown to regulate the mitochondrial-dependent pathway of apoptosis, and a selective inhibitor of PKCδ or a dominant-negative mutant of PKCδ attenuates apoptotic cell death induced by several stimuli, including glutamate, H~2~O~2~, phorbol ester, UV, taxol, and etoposide (Konishi *et al.*, [@B23]; Denning *et al.*, [@B8]; Majumder *et al.*, [@B32]; Matassa *et al.*, [@B33]; Choi *et al.*, [@B6]). In addition, smooth muscle cells derived from PKCδ knockout mice are defective in mitochondrial-dependent apoptosis, leading to a diminished cell death response to H~2~O~2~, UV, TNF-α, and IL-1β (Leitges *et al.*, [@B26]). A previous study demonstrated that an apoptotic stimulus results in proteolytic activation of PKCδ, which is inhibited by treatment with caspase inhibitors and transfection with anti-apoptotic proteins, such as Bcl-2 or Bcl-x~L~ (Emoto *et al.*, [@B11]). This observation is in agreement with previous results demonstrating that overexpression of the catalytic fragment of PKCδ, but not full-length PKCδ or a kinase-inactive fragment, was sufficient to induce apoptotic cell death (Ghayur *et al.*, [@B12]; Bharti *et al.*, [@B2]). Thus, PKCδ activity seems to have an important role in the regulation of apoptosis in a cell type--specific and context-specific manner. However, the mechanism by which activation of PKCδ drives cell death remains largely unknown (Yoshida, [@B45]).

In this study, we show that PKCδ plays a role as an upstream regulator of VRK1 in the nucleus by physically interacting with VRK1, thereby inducing its phosphorylation and down-regulation of its kinase activity. We also demonstrate that PKCδ-mediated VRK1 phosphorylation and p53 act synergistically to arrest the cell cycle and trigger cell death when DNA damage occurs.

RESULTS
=======

VRK1 associates with PKCδ in cells
----------------------------------

To identify whether PKCδ is an upstream regulatory element of VRK1, we first examined the binding between PKCδ and VRK1. mVRK1 fused with Flag epitope tag at its N terminus (Flag-VRK1) was transiently transfected into CHO-K1 cells along with PKCδ. Whole-cell lysates were subjected to immunoprecipitation with anti--Flag antibody. As seen in [Figure 1A](#F1){ref-type="fig"}, PKCδ was coimmunoprecipitated with VRK1. Proteolytic activation of PKCδ by caspases results in the generation of PKCδ catalytic fragment (PKCδ CF), which is constitutively active (Ghayur *et al.*, [@B12]; Koriyama *et al.*, [@B24]). To assess the interaction of VRK1 with PKCδ CF, cells were transfected with Flag-VRK1 and PKCδ CF, followed by immunoprecipitation with anti--Flag antibody. Interestingly, VRK1 was also coimmunoprecipitated with the PKCδ CF (Supplemental Figure 1). To investigate the endogenous interaction between PKCδ and VRK1, we performed coimmunoprecipitation assay before and after exposing the cells to DNA damage. We could detect weak endogenous interactions between PKCδ and VRK1 only under DNA-damaging conditions, suggesting that they could associate each other in the conditions of cell death ([Figure 1B](#F1){ref-type="fig"}). These data also indicate that the endogenous interaction between PKCδ and VRK1 occurs transiently for enzymatic reaction.

![VRK1 interacts with PKCδ in the nucleus. (A) Whole-cell extracts from CHO-K1 transfected with either a combination of pFlag-VRK1 and and pcDNA3-PKCδ were immunoprecipitated with anti--Flag antibody, and the precipitates, as well as the input (40 μg), were immunoblotted with antibodies to PKCδ or Flag. (B) Whole-cell extracts from HT22 cells treated with dimethyl sulfoxide or etoposide (50 μM) for 24 h were immunoprecipitated with anti--PKCδ antibody, and the precipitates were immunoblotted with antibodies to PKCδ or VRK1. (C) CHO-K1 cells were transiently transfected with a plasmid encoding GFP-PKCδ FL, GFP-PKCδ CF, or RFP-VRK1. Cells were also transfected with empty vector as controls. Nuclei were stained with Hoechst, and the localization of PKCδ and VRK1 was observed by fluorescence microscopy. (D) Cells transiently transfected with a plasmid encoding HA-PKCδ FL, PKCδ CF, or Flag-VRK1 were subjected to subcellular fractionation. Cytosol (Cyto) and nuclear (Nu) fractions were analyzed by immunoblot with antibodies to PKCδ, Flag, or lamin B.](1398fig1){#F1}

To determine whether VRK1 and PKCδ localize in the same subcellular compartment, we used a series of green fluorescent protein (GFP)-tagged full-length and catalytic fragments of PKCδ, and red fluorescent protein (RFP)-tagged VRK1. As shown in [Figure 1C](#F1){ref-type="fig"}, the cytoplasmic localization of GFP-PKCδ was more prominent than the nuclear portion, whereas GFP-PKCδ CF was predominantly distributed in the nucleus and to a lesser extent in the cytoplasm. In contrast, RFP-VRK1 was mainly localized in the nucleus ([Figure 1C](#F1){ref-type="fig"}). To confirm this result, we used subcellular fractionation of the cytoplasm and nucleus. As expected, Flag-VRK1 was identified in the nuclear fractions, whereas HA-PKCδ and PKCδ CF were recovered from both the cytoplasmic and nuclear fractions ([Figure 1D](#F1){ref-type="fig"}). These results suggest that nuclear-localized PKCδ and PKCδ CF can associate with VRK1.

PKCδ phosphorylates VRK1 on Ser-355 in vitro
--------------------------------------------

Because PKCδ CF can phosphorylate several proteins in the nucleus (Bharti *et al.*, [@B2]; Ren *et al.*, [@B39]), we examined the enzymatic activity of PKCδ in nuclear lysates from full-length PKCδ- and PKCδ CF-transfected cells using an in vitro kinase assay. As shown in [Figure 2A](#F2){ref-type="fig"}, PKCδ CF became more activated than full-length PKCδ in the nucleus. In addition, because PKCδ CF was mainly localized in the nucleus, as was VRK1 ([Figure 1](#F1){ref-type="fig"}), thereafter we only used PKCδ CF to test whether PKC is implicated in the posttranslational modification of VRK1. To determine whether VRK1 is a substrate for PKCδ, PKCδ immunoprecipitates were incubated with recombinant glutathione S-transferase (GST)-VRK1 fusion proteins. Preimmune serum (PIS) was used as a negative control. Because VRK1 has an autophosphorylating activity (Lopez-Borges and Lazo, [@B30]), phosphorylation of VRK1 was detected in an in vitro kinase assay using PIS immunoprecipitates ([Figure 2B](#F2){ref-type="fig"}). On the other hand, phosphorylation of VRK1 was more dramatically increased by PKCδ CF immunoprecipitates than by PIS ([Figure 2B](#F2){ref-type="fig"}), and its phosphorylation by PKCδ CF was confirmed using the VRK1 inactive mutant (K179E) ([Figure 2C](#F2){ref-type="fig"}), indicating that VRK1 was phosphorylated by PKCδ in vitro.

![PKCδ phosphorylates VRK1. (A) CHO-K1 cells were transfected with a plasmid encoding HA-PKCδ FL or PKCδ CF. After 24 h, the nuclear fraction was subjected to immunoprecipitation with anti-PKCδ. In vitro immune complex kinase assays were performed using histone H1 as a substrate. (B, C) Whole-cell extracts from CHO-K1 transfected with PKCδ CF were immunoprecipitated with anti--PKCδ antibody followed by in vitro immune complex kinase assay using GST-VRK1 (B) or its inactive mutant GST-VRK1 K179E (C) as substrates. The left panel shows Coomassie blue staining, and the right panel shows the incorporation of radioactivity. (D**)** A schematic representation of deletion mutants generated in the VRK1-GST fusion constructs used in subsequent experiments. (E, F) Whole-cell extracts from CHO-K1 transfected with PKCδ CF were immunoprecipitated with anti--PKCδ antibody, followed by in vitro immune complex kinase assay using GST-VRK1 full-length, deletion mutants (VRK1-N130, -M131--280, and --ΔN280) (E) or single or double amino acid substituted mutants (S355A, T390A, and S355A/T390A) (F) as substrates. The lower panel shows Coomassie blue staining, and the upper panel shows the incorporation of radioactivity. **(**G**)** Recombinant PKCδ was incubated with GST, GST-VRK1 wild type, or GST-VRK1 S355A mutant. The samples were analyzed by immunoblotting with anti--PKCδ or anti--phospho-VRK1(Ser-355) antibody, respectively.](1398fig2){#F2}

To confirm the phosphorylation of VRK1 by PKCδ, we further constructed GST-VRK1 fusion proteins carrying segments from the C or N terminus, or the internal segment of VRK1 (schematically depicted in [Figure 2D](#F2){ref-type="fig"}). Because the N-terminal portion (N130) and the internal segment (M131--280) bear an ATP-binding domain and motifs for kinase activity, respectively, autophosphorylation of GST-VRK1 mutant proteins was not detected ([Figure 2E](#F2){ref-type="fig"}). When these mutant proteins were incubated with PKCδ immunoprecipitates, only the GST-ΔN280 mutant was phosphorylated ([Figure 2E](#F2){ref-type="fig"}), confirming that the C-terminal region of VRK1 is phosphorylated by PKCδ in vitro.

Additionally, bioinformatics tools predicted that the C-terminal region of VRK1 might be phosphorylated by PKCδ. The NetworKIN database (<http://networkin.info>) provides improved information for the prediction of cellular kinase--substrate relations (Linding *et al.*, [@B29]). This database predicted that PKCδ would phosphorylate the C-terminal motif of VRK1 with the highest probability. Therefore we focused on the C-terminal portion that might have regulatory roles through specific interaction with other proteins (Lopez-Borges and Lazo, [@B30]). We tested the phosphorylation of mutant forms of GST-VRK1 in which Ser-355 or Thr-390 residues located in the C-terminal region were substituted with alanine residues. As shown in [Figure 2F](#F2){ref-type="fig"}, wild-type VRK1 and the T390A mutant were more highly phosphorylated by PKCδ than by PIS. However, the S355A mutant showed no additional phosphorylation by PKCδ compared with PIS ([Figure 2F](#F2){ref-type="fig"}). In addition, recombinant PKCδ was incubated with GST, GST-VRK1 wild type, or GST-VRK1 mutant in which Ser-355 is replaced by alanine. Kinase-active recombinant PKCδ actively phosphorylated GST-VRK1 wild type, but not GST ([Figure 2G](#F2){ref-type="fig"}). In particular, the GST-VRK1 S355A mutant showed no reactivity with anti--pSer-355 antibody. These results suggest that Ser-355 of VRK1 is a target for PKCδ, at least in vitro.

PKCδ negatively regulates VRK1 kinase activity in vitro
-------------------------------------------------------

To elucidate whether the phosphorylation of VRK1 by PKCδ affects its kinase activity, we constructed a phosphomimetic mutant, in which Ser-355 is substituted with glutamic acid (S355E). We used two typical substrates of VRK1, BAF and histone H3, to simulate the effect of PKCδ-mediated Ser-355 phosphorylation of VRK1 in vitro (Nichols *et al.*, [@B36]; Kang *et al.*, [@B21]). As expected, GST-VRK1 actively phosphorylated BAF in vitro. GST-VRK1 S355A mutant also phosphorylated BAF to the same extent as wild-type VRK1 because this mutation has no effect on its kinase activity ([Figure 3A](#F3){ref-type="fig"}). Interestingly, the GST-VRK1 S355E phosphomimetic mutant showed not only decreased autophosphorylation, but also lower kinase activity on BAF compared with the activity of wild type. Additionally, this phosphomimetic mutant also displayed decreased kinase activity on histone H3 ([Figure 3B](#F3){ref-type="fig"}). These results suggest that the phosphorylation of VRK1 by PKCδ leads to negative regulation of its kinase activity.

![PKCδ negatively regulates VRK1 kinase activity in vitro. (A, B) VRK1 kinase assay was performed using recombinant GST, GST-VRK1, GST-VRK1 S355E, or GST-VRK1 S355A. BAF (A) and histone H3 (B) were used as substrates. **(**C**)** GST pull-down assays were performed using core histone proteins with GST or GST-VRK1 wild type, GST-VRK1 S355E, or GST-VRK1 S355A, followed by immunoblotting with anti--histone H3 antibody. (D) In vitro phosphorylation assay was carried out with recombinant PKCδ and GST, GST-VRK1, or GST-VRK1 S355A in the presence of core histone as a substrate. Phosphorylations of VRK1 and core histone were analyzed by immunoblotting with anti--phospho-VRK1 (Ser-355) and anti--histone H3 (Thr-3) antibodies, respectively. (E) HEK 293T cells were transfected with plasmids encoding Flag-VRK1. After 24 h, whole-cell lysates were subjected to immunoprecipitation with anti-Flag or control IgG. In vitro immune complex kinase assays were performed using histone H3 as a substrate. Phosphorylations of VRK1 and histone H3 were analyzed by immuno­blotting with anti--phospho-VRK1 (Ser-355) and anti--histone H3 (Thr-3) antibodies, respectively.](1398fig3){#F3}

To determine whether the phosphorylation of Ser-355 could modulate VRK1 activity, we tested the association between VRK1 and its substrate, histone H3. GST pull-down assays showed that VRK1 wild type binds more efficiently to histone H3 than VRK1 S355E mutant ([Figure 3C](#F3){ref-type="fig"}). Moreover, we examined whether PKCδ downregulates VRK1 kinase activity on Thr-3 of histone H3 in vitro. When VRK1 was phosphorylated on Ser-355 by PKCδ, its kinase activity on Thr-3 of histone H3 was diminished ([Figure 3C](#F3){ref-type="fig"}).

To investigate the regulation of VRK1 activity in cells, we performed immunocomplex protein kinase assays before and after exposing the cells to DNA damage. HEK 293T cells were transfected with Flag-VRK1. Cell lysates were immunoprecipitated with anti-Flag or control immunoglobulin G (IgG), and histone H3 was used as a substrate to detect VRK1 kinase activity. Immunoblot analysis showed that the phosphorylation of VRK1 on Ser-355 was increased when cells were exposed to etoposide, whereas histone H3 phosphorylation on Thr-3 was decreased ([Figure 3E](#F3){ref-type="fig"}). Taken together, these data suggest that PKCδ is involved in the negative regulation of VRK1 through phosphorylation.

PKCδ-induced cell death is potentiated by VRK1
----------------------------------------------

To find the physiological condition in which VRK1 is phosphorylated by PKCδ, we tested the effect of VRK1 in PKCδ-induced cell death. First, we tested whether VRK1 affects cell viability. Wild-type and S355A mutant VRK1 showed little effect on CHO-K1 cell proliferation. However, the phosphomimetic mutant S355E showed an inhibitory effect on cell viability ([Figure 4A](#F4){ref-type="fig"}). This result suggests that phosphorylated VRK1 by PKCδ might be involved in the cell death pathway.

![VRK1 potentiates PKCδ-induced cell death. (A) CHO-K1 cells were transfected with mock vector, Flag-VRK1, Flag-VRK1 S355A, or Flag-VRK1 S355E. After 24 h, cell viability was measured by MTT assay, and whole-cell extracts were analyzed by immunoblotting with antibodies to Flag or GAPDH. (B, C) CHO-K1 cells were transfected with PKCδ CF alone, PKCδ CF with Flag-VRK1, or PKCδ CF with Flag-VRK1 S355A. After 24 h, cell viability was measured by MTT assay (B), and cells were viewed using fluorescence microscopy (C). Nuclei were stained with Hoechst. (D, E) C6 cells were transfected with PKCδ CF alone, PKCδ CF with Flag-VRK1, or PKCδ CF with Flag-VRK1 S355A. After 24 h, cell viability was measured by MTT assay (D), and whole-cell extracts were analyzed by immunoblotting with antibodies to cleaved caspase 3 or GAPDH (E). Results are mean ± SEM value from three separate experiments. ^\*\*^, P \< 0.01. (F) **C**HO-K1 cells were transiently transfected with a plasmid encoding dsRed-VRK1 wild type or its S355A mutant. Nuclei were stained with Hoechst, and the nuclear morphology was observed by using fluorescence microscope. (G) CHO-K1 cells were transfected with PKCδ CF alone, PKCδ CF with Flag-VRK1, or PKCδ CF with Flag-VRK1 S355A. After 24 h, cells were fixed with 70% ethanol and stained with propidium iodide. Sub-G1 population was analyzed by flow cytometry.](1398fig4){#F4}

As mentioned, VRK1 mainly resides in the nucleus because it has a nuclear localization signal. A previous study demonstrated that overexpression of PKCδ CF results in nuclear localization and regulates an essential nuclear event that is required for activation of the apoptotic pathway (DeVries *et al.*, [@B9]). Therefore we reasoned that PKCδ might interact with VRK1 in the nucleus in certain conditions, such as apoptotic cell death. We thus examined whether overexpression of PKCδ CF induces cell death in CHO-K1 cells. On the basis of the MTT assay, we found that more than 30% of the cells underwent cell death ([Figure 4B](#F4){ref-type="fig"}). As we previously showed that PKCδ contributes to regulation of VRK1 activity in vitro, we next investigated whether VRK1 is involved in PKCδ CF--induced cell death. Interestingly, PKCδ CF--induced cell death was synergistically increased when cells were transfected with VRK1 ([Figure 4, B and C](#F4){ref-type="fig"}), and more dramatic results were obtained from the MTT assay and cleaved caspase-3 in transfected C6 glioma cells ([Figure 4, D and E](#F4){ref-type="fig"}), suggesting that VRK1 participated in the potentiation of PKCδ CF--induced cell death. On the other hand, the VRK1-S355A mutant itself did not affect cell viability but completely rescued the effect of wild-type VRK1 on PKCδ-induced cell death ([Figure 4, B and D](#F4){ref-type="fig"}). These results suggest that negative regulation of VRK1 activity plays an important role in PKCδ-induced cell death. Moreover, VRK1 S355A mutant retained its kinase activity and abrogated PKCδ-induced cell death. This result also supports the notion that the VRK1 S355A mutant might have a dominant negative effect against VRK1 in cell death conditions. In addition, both VRK1-WT and VRK1-S355A mutant are localized in the nucleus. As shown in [Figure 4F](#F4){ref-type="fig"}, ds-Red VRK1-S355A mutant is located in the nucleus like wild-type VRK1.

We additionally performed the flow cytometric analysis to verify the role of VRK1 in PKCδ-induced apoptosis. As shown in [Figure 4G](#F4){ref-type="fig"}, apoptotic cell population (sub-G1) was increased when cells were cotransfected with PKCδ CF and VRK1-WT. However, apoptotic cell death was diminished when cells were cotransfected with PKCδ CF and VRK1-S355A mutant. This result is correlated with MTT and active caspase-3 assay.

PKCδ phosphorylates VRK1 in DNA damage-induced cell death
---------------------------------------------------------

To clarify the association between PKCδ and VRK1 in the apoptotic pathway, we checked whether endogenous VRK1 is phosphorylated on Ser-355 by PKCδ in DNA damage--induced cell death. HT22 cells were treated with etoposide to induce DNA damage and apoptosis. As expected, apoptotic cell death signaling was evident when the increase in cleaved caspase-3 and PKCδ catalytic fragment were measured during the incubation period ([Figure 5A](#F5){ref-type="fig"}). Interestingly, the level of pSer355-VRK1 was elevated as apoptotic cell death progressed, even though the level of VRK1 was also augmented by etoposide treatment. In HEK293T cells, the level of human VRK1 was also increased in etoposide-induced cell death (Supplemental Figure 2). Etoposide induces G~2~/M arrest in a variety of cell lines (Wei *et al.*, [@B44a]). We have previously reported that VRK1 expression is regulated in a cell cycle--dependent manner (Kang *et al.* [@B21]). The expression level of VRK1 reached the highest point in G~2~/M phase. That might be the reason why the expression of VRK1 is increased by etoposide.

![PKCδ is involved in phosphorylation of VRK1 on Ser-355 in response to DNA damage. (A) HT22 cells were treated with etoposide (50 μM) for the indicated times. Cell lysates were subjected to immunoblot with specified antibodies. (B) HT22 cells transfected with control scramble siRNA or PKCδ siRNA were left untreated or treated by etoposide. After 24 h, cell lysates were subjected to immunoblot with specified antibodies. (C) HT22 cells were transfected with enhanced green fluorescent protein (EGFP), EGFP-PKCδ CF, or EGFP-PKCδ CF DN. After 24 h, cell lysates were subjected to immunoblot with specified antibodies. (D) HT22 cells transfected with control scramble siRNA or VRK1 siRNA were cotransfected with EGFP, EGFP-PKCδ CF, or EGFP-PKCδ. After 24 h, cell lysates were subjected to immunoblot with specified antibodies.](1398fig5){#F5}

When PKCδ was depleted in cells, the phosphorylation on S355 of VRK1 was diminished as well as the apoptotic cell death in response to etoposide ([Figure 5B](#F5){ref-type="fig"}). In addition, expression of PKCδ CF dominant negative mutant relieved the etoposide-induced phosphorylation of VRK1 on Ser-355 ([Figure 5C](#F5){ref-type="fig"}). Collectively, these data indicate that the PKCδ catalytic fragment phosphorylates VRK1 in the nucleus during apoptotic cell death.

To further verify the role of VRK1 in PKCδ-mediated cell death, we knocked down VRK1 by introducing VRK1 small interfering (si)RNAs. As shown in [Figure 5D](#F5){ref-type="fig"}, knocking down of VRK1 was associated with the attenuation of apoptotic cell death induced by PKCδ CF. This result also supports the role of VRK1 in conjunction with PKCδ in apoptotic cell death.

Phosphorylation of VRK1 by PKCδ is required for the p53-dependent cell death pathway
------------------------------------------------------------------------------------

A recent study demonstrated that VRK1 might function as a switch controlling the proteins that interact with p53 and thus modifying p53 stability and activity during cell proliferation (Vega *et al.*, [@B44]). We therefore examined whether p53 was involved in our system. For this purpose, we first examined the effect of etoposide on cellular p53 levels. In agreement with previous studies (Blass *et al.*, [@B3]; Jinag *et al.*, [@B18]), etoposide elicited accumulation of the p53 protein in the nucleus and nuclear translocation of the catalytic fragment of PKCδ ([Figure 6, A and B](#F6){ref-type="fig"}). Next we examined changes in the levels of endogenous p53 protein in DNA damage--induced cell death. A slight increment in levels of p53 protein was detected in C6 glioma cells transfected with wild-type VRK1 ([Figure 6, C and D](#F6){ref-type="fig"}), suggesting that p53 might be involved in VRK1-induced cell death.

![Involvement of p53 in VRK1-mediated cell death induced by PKCδ. (A) C6 cells treated with etoposide (50 μM) for 12 h were subjected to subcellular fractionation. Cytosol (Cyto) and nuclear (Nu) fractions were analyzed by immunoblot with antibodies to PKCδ, p53, or Lamin. (B) C6 cells were treated with etoposide (50 μM) for 12 h, and the accumulation of p53 in the nucleus was assessed using immunofluorescence staining. (C) C6 cells overexpressing mock vector, Flag-VRK1, or Flag-VRK1 S355A were treated with or without etoposide (50 μM) for 8 h. Cell viability was measured by MTT assay. (D) Whole-cell extracts were analyzed by immunoblot with antibodies to p53, cleaved caspase 3, or GAPDH. ^\*\*^, P \< 0.01.](1398fig6){#F6}

To further investigate the effect of p53 on PKCδ-mediated VRK1 modulation, we used p53-deficient H1299 cells. Cells were transfected with plasmids expressing wild-type VRK1 or its S355A mutant, with or without PKCδ CF plasmid, and the MTT assay was performed. Interestingly, the effect of VRK1 and PKCδ on cell viability was not observed in p53 knockout cells ([Figure 7A](#F7){ref-type="fig"}). On the other hand, p53 overexpressing H1299 cells exhibited significant reduction of cell viability when the cells were cotransfected with both VRK1 and PKCδ CF ([Figure 7B](#F7){ref-type="fig"}). The role of p53 was confirmed by its ability to increase the level of cleaved caspase-3 in cells cotransfected with VRK1 and PKCδ ([Figure 7C](#F7){ref-type="fig"}).

![p53 is involved in VRK-1-mediated cell death induced by PKCδ. (A) H1299 (p53 null) cells were transfected with a plasmid encoding wild-type VRK1 or its S355A mutant either alone or together with PKCδ. Cells were also transfected with empty vector or PKCδ alone as controls. After 24 h, cell viability was measured by MTT assay, and whole-cell extracts were analyzed by immunoblot with antibodies to Flag, PKCδ, or GAPDH. (B, C) H1299 (p53 null) cells were cotransfected with a plasmid encoding wild-type VRK1 or its S355A mutant either alone or together with PKCδ or PKCδ dominant negative in the presence of p53. After 24 h, cell viability was measured by MTT assay, and whole-cell extracts were analyzed by immunoblotting with antibodies to Flag, PKCδ, p53 (B), or cleaved caspase 3 (C). Results are mean ± SEM value from three separate experiments. ^\*\*^, P \< 0.01 value compared with p53 alone.](1398fig7){#F7}

Actually, overexpression of PKCδ CF showed little effect on apoptosis in p53-deficient H1299 cells ([Figure 7A](#F7){ref-type="fig"}). However, HCT116 (p53 ^−/−^) and HL60 (p53 ^−/−^) cells are sensitive to PKCδ CF--induced apoptosis even though they do not express p53 (Supplemental [Figure 3, A and C](#F3){ref-type="fig"}). Notably, apoptotic cell death by PKCδ and VRK1 is also dramatically potentiated in the presence of wild-type p53 both in HCT116 (p53 ^−/−^) and HL60 (p53 ^−/−^) cells (Supplemental Figure 3, B and D). Taken together, these results suggest that p53 plays an important role in the regulation of cell death accompanied by PKCδ-mediated phosphorylation of VRK1.

DISCUSSION
==========

In the present study, we suggest that PKCδ plays an important role as an upstream regulator of VRK1 in the nucleus and contributes to the acceleration of apoptotic cell death following the DNA damage response. This study also provides evidence that phosphorylation of VRK1 on Ser-355 by PKCδ is required for the induction of the p53-dependent cell death pathway.

The distinct pattern of subcellular localization of PKCδ in response to various stimuli may determine the effects of PKCδ on cell apoptosis. For example, when cells overexpressing PKCδ were treated with phorbol ester, PKCδ translocated to the mitochondria, resulting in loss of mitochondrial membrane potential and release of cytochrome c (Li *et al.*, [@B28]; Majumder *et al.*, [@B32]). In addition, PKCδ translocated to the nucleus in response to etoposide, followed by elevation of caspase-3 activity in C6 glioma cells (Blass *et al.*, [@B3]). Translocation of PKCδ to specific cellular compartments may lead to the phosphorylation of specific substrates and to the association of PKCδ with distinct proteins present in these locations (Brondie and Blumberg, [@B5]). Until now, a number of downstream targets of PKCδ have been described in different cellular systems. Some of these PKCδ substrates are nuclear proteins that participate in cell apoptosis. One of these proteins is the DNA-dependent protein kinase (DNA-PK), an enzyme essential for the repair of double-stranded DNA breaks that is inhibited by PKCδ-dependent phosphorylation (Bharti *et al.*, [@B2]). Rad9, a key component of the genotoxin-activated checkpoint signaling complex, also binds to anti--apoptotic Bcl-2 family proteins and mediates apoptotic responses to DNA damage when phosphorylated by PKCδ (Yoshida *et al.*, [@B46]). In addition, it has been reported that lamin B and p73β are nuclear substrates of PKCδ involved in apoptotic cell death (Cross *et al.*, [@B7]; Ren *et al.*, [@B39]). Here we show that both full-length PKCδ and its catalytic fragment associated with VRK1 ([Figure 1A](#F1){ref-type="fig"}), causing VRK1 phosphorylation on Ser-355 residue ([Figure 2](#F2){ref-type="fig"}) and negatively regulating its kinase activity ([Figure 3](#F3){ref-type="fig"}) in vitro.

We propose that VRK1 is one of the downstream targets of PKCδ in the nucleus that might contribute to PKCδ-induced apoptotic cell death. Under physiological conditions, the majority of VRK1 is localized in the nucleus, with some present in the perinuclear area (Vega *et al.*, [@B44]), in agreement with our present results ([Figure 1](#F1){ref-type="fig"}). In contrast, PKCδ is predominantly distributed in the cytoplasm, showing a punctate, perinuclear distribution (DeVries *et al.*, [@B9]). However, we found that overexpressed full-length PKCδ and its catalytic fragment were also distributed in the nucleus ([Figure 1, B and C](#F1){ref-type="fig"}). We showed that PKCδ-induced cell death is potentiated by wild-type VRK1, but not the S355A mutant, suggesting that phosphorylation of VRK1 by PKCδ plays a critical role in cell cycle arrest and cell death ([Figure 4B](#F4){ref-type="fig"}).

VRK1 leads to p53 accumulation and transcriptional activity (Vega *et al.*, [@B44]). Moreover, a recent study indicated that PKCδ functions downstream of the p53 response in DNA damage--induced apoptosis in vivo and in vitro (Humphries *et al.*, [@B17]). Thus, we focused on the possible role of VRK1 in the PKCδ-induced apoptotic cell death following the DNA damage response. Surprisingly, the effect of VRK1 and PKCδ on cell death was not apparent in p53-depleted H1299 cells ([Figure 7A](#F7){ref-type="fig"}). Furthermore H1299 cells overexpressing p53 exhibited significant reduction of cell viability when the cells were cotransfected with both VRK1 and PKCδ ([Figure 7B](#F7){ref-type="fig"}). The effect of p53 on cell death was confirmed by its ability to increase the level of cleaved caspase-3 in cells cotransfected with VRK1 and PKCδ ([Figure 7C](#F7){ref-type="fig"}), demonstrating that p53 plays a critical role in the regulation of cell death concomitant with PKCδ-mediated VRK1 phosphorylation.

The mammalian VRK family and the related vaccinia virus B1R kinase are classified as a distinct branch of the casein kinase-1 group, and their biological roles are less well known compared with other kinases in the kinome (Gross and Anderson, [@B15]). A recent study demonstrated that VRK1 might play a role in enabling DNA replication. This study showed that expression of VRK1 from the temperature-sensitive mutant B1 vaccinia virus genome restored viral DNA replication, whereas a catalytically inactive mutant of VRK1 was not able to rescue the virus (Boyle and Traktman, [@B4]). In addition, VRK1 was also implicated in cell cycle progression. Suppression of VRK1 expression by specific small interfering RNA (siRNA) leads to a retardation of cell division and proliferation (Vega *et al.*, [@B44]), and ablation of the *Caenorhabditis elegans* VRK homolog through the use of siRNA-mediated depletion resulted in early embryonic lethality due to a problem in cell cycle progression (www.wormbase.org). In addition, VRK1 phosphorylates histone H3 on Thr-3 and Ser-10, resulting in chromatin condensation and cell division (Kang *et al.*, [@B21]). These recent findings collectively support the notion that VRK1 is a positive regulator for cell proliferation and cell cycle progression. Therefore it is conceivable that the kinase activity of VRK1 needs to be down-regulated in conditions where cells are undergoing cell cycle arrest and death. This study suggests that VRK1 is negatively regulated by PKCδ in DNA damage--induced cell death conditions for cell cycle arrest and activation of apoptotic pathways. It is probable that Ser-355 phosphorylated VRK1 associates with another nuclear target to regulate p53-dependent cell death pathway, even though its kinase activity is down-regulated.

Thus we propose a dual model of VRK1 function in cell proliferation and death ([Figure 8](#F8){ref-type="fig"}). In cell proliferation conditions, VRK1 is mainly localized in the nucleus and phosphorylates several nuclear targets essential for cell cycle progression and division, such as CREB, histone H3, and BAF. On the contrary, in cell death conditions, VRK1 is phosphorylated by PKCδ and contributes to cell cycle arrest and apoptosis.

![Hypothetical model: dual signaling pathways of VRK1. In cell proliferation conditions, VRK1 is mainly localized in the nucleus and phosphorylates several nuclear targets essential for cell cycle progression and division, such as CREB, histone H3, and BAF. On the contrary, in cell death conditions, VRK1 is phosphorylated by PKCδ and contributes to cell cycle arrest and apoptosis.](1398fig8){#F8}

Taken together, it is concluded that the active form of PKCδ is translocated into the nucleus, where PKCδ associates with VRK1, leading to down-regulation of its kinase activity and thus accelerating cell cycle arrest and activation of apoptotic pathways via a p53-dependent mechanism.

MATERIALS AND METHODS
=====================

Reagents and antibodies
-----------------------

Histone H1 and etoposide were purchased from Calbiochem (La Jolla, CA). \[γ-^32^P\]ATP was from NEN Life Science Products (Boston, MA). Recombinant PKCδ was from Upstate Biotechno­logy (Lake Placid, NY). The anti--Flag antibody was purchased from Sigma (St. Louis, MO). Polyclonal antibodies against PKCδ and lamin B and monoclonal antibody (mAb) against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were from Santa Cruz Biotechnology (Santa Cruz, CA), and mAb against p53 and polyclonal antibody against cleaved caspase-3 were from Cell Signaling Technology (Beverly, MA).

Plasmids
--------

We obtained 1191 base pairs ORF of mVRK1 from mouse liver cDNA, which is splice variant lacking exon 12 and 13 of mVRK1. Amplification of cDNA was performed with *pfu* polymerase (Solgent, Daejon, Republic of Korea) and a primer pair specific for the VRK1 coding region (forward 5′-AAAGATCTAATGCCCCGTGTAAAAGCAGC-3′ and reverse 5′-AATCTAGATTACTTCTGGGCTTTCTTTC-3′). The amplified DNA fragment was digested with *Bgl*II and *Xba*I and cloned into pFlag-CMV-1 (Sigma). This construct was used as a template to produce phosphorylation mutant constructs and kinase inactive mutant. VRK1 mutations S355A, T390A, and K179E were generated using complementary oligonucleotides containing the mutation desired, and also cloned into pFlag-CMV-1. All mutations were confirmed by DNA sequencing. VRK1 and mutants fused to RFP were cloned into the *Xho*I and *Bam*HI sites of pDsRed1-C1 (Clontech, Mountain View, CA). Mouse PKCδ cloned into pHACE vector was generously provided by Y. S. Lee (Lee *et al.*, [@B25]). The constitutive active form of PKCδ (amino acids 325--674, CAT) was prepared by subcloning the PCR-amplified fragment into pcDNA3.1. Wild-type PKCδ and PKCδ-CAT fused to GFP were cloned into the *Xho*I and *Bam*HI sites of pEGFP-C1 (Clontech).

Preparation of recombinant VRK1 proteins
----------------------------------------

Complete VRK1 coding region, the deletion mutants, and the phosphorylation mutants were cloned into pGEX-4T-1 (Pharmacia Biotech, Uppsala, Sweden). The deletion mutant constructs including the amino acid fragments 1-130 (N130), 131-280 (131--280), and 281-396 (ΔN280) were generated by PCR-based amplification. The resulting plasmids were transformed into *Escherichia coli* BL21(DE3) to produce GST tag-VRK1 fusion proteins after treating with 0.1 M isopropyl-1-thio-β-[d]{.smallcaps}-galactopyranoside for 24 h at 16°C. Bacteria were lysed in phosphate-buffered saline (PBS) containing 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 mM Na~3~VO~4~. The GST fusion proteins were then purified using glutathione-sepharose resin (Amersham Biosciences, Little Chalfont, UK) and eluted from the beads with reduced glutathione according to the manufacturer's recommendations. The mutant constructs were confirmed by DNA sequencing.

Preparation of anti--mouse VRK1 antibody
----------------------------------------

Mouse VRK1 antisera were generated in rabbit using recombinant mouse VRK1 (accession no. NM 011705.3) as immunogen. Approximately 1 mg of recombinant mouse VRK1 was used to immunize rabbit with complete Freund's adjuvant through subcutaneous injection. After 2 wk of first immunization, the rabbit was boosted once again using incomplete adjuvant. Then, the rabbit was boosted once more with only recombinant protein after 2 wk of second immunization. Rabbit serum was collected and then subjected to HiTrap Protein G column (GE Healthcare, Uppsala, Sweden) for affinity purification. Phosphorylated Ser-355 of mouse VRK1 was raised against peptides VKTRPApSKK.

Cell culture and transfection
-----------------------------

CHO-K1 cells were maintained in DMEM/F12 containing 10% bovine calf serum and antibiotics in a humidified 5% CO~2~ incubator at 37°C. H1299 (human lung cancer cell line, p53^−/−^) was grown in RPMI 1640 containing 10% fetal calf serum (FCS), glutamine, HEPES, and antibiotics in a humidified 5% CO~2~ incubator at 37°C. C6 glioma cells were cultured in DMEM containing 10% FCS and antibiotics in a humidified 5% CO~2~ incubator at 37°C. CHO-K1 cells were transfected by the electroporation method with the plasmid indicated in the specific experiments. After incubation for 24 h, the transfected cells were treated as indicated for analysis. H1299 and C6 cells were transfected with the plasmid indicated in the specific experiments by using Metafectene reagent (Biontex, Munich, Germany). After incubation for 24 h, the transfected cells were treated as indicated for analysis.

Cytoplasmic and nuclear fractionation
-------------------------------------

Cells were resuspended in hypotonic buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl~2~, 1 mM DTT, 0.2 mM PMSF, and 0.5% Nonidet P-40) and incubated at 4°C for 30 min. Samples were agitated every 10 min and then centrifuged at 3500 rpm for 4 min to collect the cytoplasmic fraction. To isolate nuclei, pellets were resuspended, incubated in nuclear extraction buffer (20 mM HEPES, 450 mM NaCl, 1.5 mM MgCl~2~, 1 mM DTT, and 0.2 mM PMSF) for 20 min, and then repeated freezing and thawing five times. The nuclear suspension was centrifuged at 15,000 rpm for 20 min to obtain the nuclear fraction.

Immunoblotting and immunoprecipitation
--------------------------------------

Immunoblot analysis was performed as we previously described (Choi *et al.*, [@B6]). For immunoprecipitation, cell lysates were prepared in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 10 μg/ml pepstatin A, 10 μg/ml leupeptin, 1 mM PMSF, 10 μg/ml aprotinin, 10 mM NaF, and 1 mM Na~3~VO~4~). Equal amounts of proteins were immunoprecipitated using anti--PKCδ and anti--Flag antibodies and collected with protein A-Sepharose beads (Santa Cruz Biotechnology) at 4°C for 16 h. The immunoprecipitate was then washed four times in cold lysis buffer and subjected to Western blot analysis and PKCδ kinase assay.

PKCδ kinase assay
-----------------

The activity of PKCδ was determined by immune complex kinase assay as previously described (Choi *et al.*, [@B6]). Briefly, the anti--PKCδ immunoprecipitate was washed in a kinase reaction buffer (25 mM Tris-HCl, pH 7.5, 5 mM β-glycerol phosphate, 2 mM DTT, 0.1 mM sodium orthovanadate, and 10 mM MgCl~2~). The kinase assay was carried out in a total volume of 30 μl of a kinase reaction buffer containing 50 μM ATP, 1 μCi of \[γ-^32^P\]ATP, and affinity-purified GST fusion proteins or 200 μg/ml histone H1 used as substrates for 30 min incubation at 30°C. The phosphorylated proteins were resolved on 10% SDS-polyacrylamide gels followed by autoradiography.

VRK1 protein kinase assay
-------------------------

The kinase activity was performed as previously described (Vega *et al.*, [@B44]). Briefly, aliquots of GST fusion proteins were resuspended in kinase reaction buffer (20 mM Tris-HCl, pH 7.5, 5 mM MgCl~2~, 0.5 mM DTT, and 150 mM KCl) and incubated for 30 min at 30°C with 1 μCi of \[γ-^32^P\]ATP and 1 μg myelin basic protein used as substrate. Substrate phosphorylation was detected by autoradiography.

Cell viability assay
--------------------

Cell viability was assessed by measuring their ability to metabolize 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as we described in detail elsewhere (Choi *et al.*, [@B6]).

siRNA experiments
-----------------

siRNA duplexes targeting VRK1 and PKCδ were purchased from Dharmacon (Lafayette, CO). Transfection of siRNA duplexes was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or Neon transfection system (Invitrogen).

Immunofluorescence staining and immunocytochemical analysis
-----------------------------------------------------------

Cells were grown on coated glass coverslips. Then, 24 h posttransfection, cells were fixed with 4% paraformaldehyde (PFA) in PBS for 30 min at 4°C and then washed in PBS. Slides were mounted and visualized by fluorescence microscopy (Axioplan2; Zeiss, Oberkochen, Germany). For immunocytochemistry, etoposide-treated C6 cells were fixed with 4% PFA and then incubated with blocking solution (2.5% bovine serum albumin and 2.5% equine serum in PBS) for 1 h at room temperature. The samples were incubated overnight at 4°C with monoclonal anti--p53 antibody, followed by incubation with FITC-conjugated anti--mouse IgG. Slides were mounted and visualized by fluorescence microscopy. Postacquisition processing of images was performed with Adobe Photoshop 7.0 software.

Statistical analysis
--------------------

All traces and immunoblots presented are representative of three separate experiments. All quantitative data are presented as means ± SEM of a minimum of three experiments. Comparisons between two groups were analyzed via *t* test, and values of P \< 0.05 were considered to be significant.
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CF

:   catalytic fragment

DN

:   dominant negative

EGFP

:   enhanced green fluorescent protein

GAPDH

:   glyceraldehyde 3-phosphate dehydrogenase

IgG

:   immunoglobulin G

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

PKCδ

:   protein kinase Cδ

siRNA

:   small interfering RNA

VRK1

:   vaccinia-related kinase 1
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